




RealRate

PHARMACEUTICAL 2017

Relmada Therapeutics INC
Rank 123 of 308



The relative strengths and weaknesses of Relmada Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Relmada Therapeutics INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 151% points. The greatest weakness of Relmada Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 292%, being 47% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	9,298
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,061
Liabilities, Non-Current	141
Other Assets	414
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	13,241
Other Revenues	0
Property and Equipment	531
Research and Development	6,207
Selling, General and Administrative Expense	10,009

Output Variable	Value in 1000 USD
Assets	10,244
Liabilities	3,202
Expenses	16,216
Revenues	0
Stockholders Equity	7,042
Net Income	-2,975
Comprehensive Net Income	-2,975
BaseVar	21,451
ECR before LimitedLiability	184%
Economic Capital Ratio	292%